InMed Pharmaceuticals Inc
INM
Company Profile
Business description
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
Contact
885 West Georgia Street
Suite 1445
VancouverBCV6C 3E8
CANT: +1 604 669-7207
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2027
Employees
13
Stocks News & Analysis
stocks
Major ASX miner reduces aluminium exposure
The Alcoa transaction unlocks value and sharpens ASX miners focus on base metals.
stocks
Vegemite owner’s shares remain expensive on normalising profits.
Australian dairy staple to see profits normalise with shares screening as overvalued.
stocks
Ask the analyst: Where does GYG stand following its US exit?
All roads lead back home for Guzman Y Gomez.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,037.00 | 11.20 | 0.12% |
| CAC 40 | 8,473.64 | 34.43 | -0.40% |
| DAX 40 | 25,795.03 | 15.72 | 0.06% |
| Dow JONES (US) | 52,816.07 | 84.00 | -0.16% |
| FTSE 100 | 10,630.42 | 48.61 | -0.46% |
| HKSE | 23,616.32 | 266.29 | 1.14% |
| NASDAQ | 26,125.54 | 292.87 | 1.13% |
| Nikkei 225 | 69,737.69 | 6.38 | -0.01% |
| NZX 50 Index | 13,763.10 | 144.68 | 1.06% |
| S&P 500 | 7,527.65 | 44.41 | 0.59% |
| S&P/ASX 200 | 8,831.00 | 12.70 | 0.14% |
| SSE Composite Index | 4,041.24 | 2.41 | -0.06% |